Skip to content

Flatiron Health at ISPOR Europe 2025

Booth #515

Flatiron is excited to attend and present our research at ISPOR Europe 2025, showcasing how our global evidence solutions deliver real-world insights that power value and access decisions worldwide.

Meet us in Glasgow

We know oncology data. We deliver oncology evidence.

At Flatiron, we are unlocking HEOR evidence and insights to demonstrate the value of oncology treatments to stakeholders including payers, regulators, and providers. By leveraging our industry leading multinational oncology data assets from the US, UK, Germany, and Japan and unparalleled expertise, we’re generating a spectrum of tailored solutions configured for the specific evidence needs of life sciences companies. 

The research showcases innovative approaches to real-world evidence—from transportability studies and cross-border data harmonization to bias assessments in AI-extracted data—that address the most challenging questions in the field and advance the science of what real-world evidence can achieve.

Join our experts at booth #515 to discover how Flatiron is transforming the possibilities of oncology research, development, and access.

 

SCROLL TO:

Flatiron networking reception

Monday, November 10, 2025

19:30-22:30 GMT

Join us for an evening of networking, cocktails, and hors d’oeuvres. This is a great opportunity to connect with colleagues, industry peers, and the Flatiron team.

RSVP now

Speaking sessions

Is Transferring Evidence Across Europe a Herculean Task? The Opportunities and Challenges of Transportability Analyses in the Context of European Union Joint Clinical Assessments

Monday, November 10

13:45-14:45 GMT

This workshop offers an interactive, deep dive into transportability analyses, a crucial method for addressing the deprioritization of real-world evidence (RWE) and the harmonization challenges under the new EU HTA Regulation's Joint Clinical Assessment (JCA). Through a framework presentation, a hypothetical JCA case study, and discussion of novel methodologies like estimands, attendees will learn how to leverage international RWE to bolster evidence submissions and validate comparative effectiveness in this evolving regulatory landscape.

View session info
Blythe-Adamson

presenter

Blythe Adamson, PhD, MPH

Head of Outcomes Research & Evidence Generation, International

Operationalizing Life-Cycle Health Technology Assessment for Precision Medicine

Monday, November 10

17:00-18:00 GMT

This session is critical for stakeholders facing market access challenges for highly uncertain precision medicine technologies. The panel will introduce an operational LC-HTA framework and use an entrectinib case study to demonstrate advanced RWE generation, including target trial emulation and data fusion, for establishing comparative effectiveness and evolving value-for-money. This provides actionable strategies for planning global evidence and ensuring RWE transportability across international regulatory and reimbursement systems.

View session info
Blythe-Adamson

presenter

Blythe Adamson, PhD, MPH

Head of Outcomes Research & Evidence Generation, International

Global evidence solutions

Real-World Data

Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.

Real-World Evidence Services

Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your oncology portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.

Flatiron FORUM

Flatiron FORUM is our multi-stakeholder research collaboration that brings together Life Science Companies, HTA bodies and academics with the goal of enabling better HTA decision-making through the exemplar use of RWE and research methods.

Meet our experts at booth #515

Blythe-Adamson

Blythe Adamson, PhD, MPH

Head of Outcomes Research & Evidence Generation, International

lockwood-taylor

Lockwood Taylor, PhD

Senior Director, Head of Regulatory Strategy

Arun Sujenthiran

Arun Sujenthiran, MD

Clinical Lead, International

Our research

Read more about our accepted research at this year’s conference.

Descriptive Comparison of Patient Characteristics and Treatment Patterns in Metastatic NSCLC: US and France Cohorts to Inform Transportability

TOP 5% FINALIST

Author affiliations: Flatiron Health, Unicancer, Institut Claudius Régaud, PSL Research University, Daiichi Sankyo, Centre Léon Bérard, CHI Créteil, Institut Curie, Groupe hospitalier de la région de Mulhouse Sud Alsace, CHU Montpellier, CHU Rennes

Using data from the US-based Flatiron Health Research Database and the French ESME database, this study compares patient characteristics and first-line treatment patterns in mNSCLC between the US and France, improving understanding of when and how evidence is transportable in oncology.

Read more

See this research

Date: Monday, November 10
Poster Session 2
Poster Code: RWD56

Connect with a flatiron expert

Philani M headshot team page

Philani Mpofu
Senior Research Scientist
Connect on LinkedIn

 

Are Real-World Survival Outcomes in Metastatic Breast Cancer Transportable Between the US and Austria?

TOP 5% FINALIST

Author affiliations: Flatiron Health, UMIT TIROL, Daiichi Sankyo, Roche, AGMT, Paracelsus Medical University

Using data from the US-based Flatiron Health Research Database and the Austrian AGMT registry, this study assesses whether survival outcomes for patients with metastatic breast cancer were transportable between the US and Austria, improving understanding of when and how evidence is transportable in oncology.

Read more

See this research

Date: Tuesday, November 11
Poster Session 4
Poster Code: HTA38

Connect with a flatiron expert

harlan pittell

Harlan Pittell
Senior Research Scientist
Connect on LinkedIn

 

Advancing Real-World Evidence in Diffuse Large B-Cell Lymphoma: Insights from EHR-Derived Data in the UK

Author affiliations: Flatiron Health

This study fills critical gaps in existing data and provides insight into patient demographics, clinical/disease characteristics, testing results, treatment regimens, and mortality of patients with diffuse large B-cell lymphoma cancer in the UK.

Read more

See this research

Date: Monday, November 10
Poster Session 1
Poster Code: HSD4

Connect with a flatiron expert

Elsie-Horne---Data-Scientist

Elsie Horne
Research Scientist
Connect on LinkedIn

 

Comparing Countries' Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States

Author affiliations: Flatiron Health, Roche

This study uses data from the US-based Flatiron Health Research Database and the Austrian AGMT registry to compare time to treatment initiation for patients with metastatic breast cancer across countries, improving understanding of when and how evidence is transportable in oncology.

Read more

See this research

Date: Monday, November 10
Poster Session 1
Poster Code: HSD26

Connect with a flatiron expert

harlan pittell

Harlan Pittell
Senior Research Scientist
Connect on LinkedIn

 

Assessing Bias in LLM-Extracted Real-World Data: A Health Equity Analysis of Access to Care and Outcomes in Metastatic Breast Cancer

Author affiliations: Flatiron Health

This study assesses the fairness of LLMs by comparing their data extraction capabilities to human abstraction in evaluating racial and ethnic inequities in biomarker testing and overall survival among patients with HR+/HER2- metastatic breast cancer.

Read more

See this research

Date: Monday, November 10
Poster Session 1
Poster Code: MSR39

Connect with a flatiron expert

olive-mbah

Olive Mbah
Senior Health Equity Scientist
Connect on LinkedIn

 

Fit-for-Purpose Real-World Data: Lessons from FDA QCARD and EMA Data Quality Framework

Author affiliations: Flatiron Health

This study provides a detailed comparison to identify opportunities for sponsors to streamline high-quality submissions of RWD/E to both regulators, which could enhance the global use of RWD in regulatory contexts.

Read more

See this research

Date: Monday, November 10
Poster Session 5
Poster Code: HPR96

Connect with a flatiron expert

angela chen

Angela Chen
Regulatory Affairs Strategist
Connect on LinkedIn

 

Laboratory Testing Patterns in Patients with Breast Cancer Treated With CDK4/6 Inhibitors: A Multi-Country Electronic Health Record Study From the UK, Germany, and Japan

Author affiliations: Flatiron Health

This study explores the use of electronic health records to monitor liver function tests in patients with breast cancer treated with CDK4/6 inhibitors across the UK, Germany, and Japan, highlighting the feasibility of using EHR-derived data to track laboratory tests and potentially enhance drug safety surveillance.

Read more

See this research

Date: Tuesday, November 11
Poster Session 2
Poster Code: SA59

Connect with a flatiron expert

Elsie-Horne---Data-Scientist

Elsie Horne
Research Scientist
Connect on LinkedIn

 

Incidence of Neutropenia Adverse Events Identified in Electronic Health Care Records Among Initiators of CDK4/6 Inhibitors With Advanced Breast Cancer in the UK

Author affiliations: Flatiron Health

This study assesses the incidence of neutropenia among women with advanced breast cancer treated with CDK4/6is as captured in structured EHR-data, laying the foundation for the potential development and implementation of a safety surveillance system using EHR-data.

Read more

See this research

Date: Tuesday, November 11
Poster Session 3
Poster Code: EPH143

Connect with a flatiron expert

lockwood-taylor

Lockwood Taylor
Senior Director, Head of Regulatory Strategy
Connect on LinkedIn

 

Transportability of Overall Survival in Multiple Myeloma From the US to Germany: A Benchmarking Study

Author affiliations: Flatiron Health, Roche

In this study, data from the US-based Flatiron Health Research Database and the GermanOncology Registry are used to examine whether overall survival estimates from patients with multiple myeloma in the US can be transported to Germany.

Read more

See this research

Date: Tuesday, November 11
Poster Session 5
Poster Code: HTA340

Connect with a flatiron expert

Elsie-Horne---Data-Scientist

Elsie Horne
Research Scientist
Connect on LinkedIn

 

Real-World Insights into Prostate Cancer Management Using EHR-Derived Data from the UK

Author affiliations: Flatiron Health

This study addresses critical gaps in existing data by providing insights into patient demographics, clinical characteristics, biomarker testing, treatment regimens, and mortality of patients with prostate cancer in the UK.

Read more

See this research

Date: Wednesday, November 12
Poster Session 4
Poster Code: RWD161

Connect with a flatiron expert

Elsie-Horne---Data-Scientist

Elsie Horne
Research Scientist
Connect on LinkedIn

 

Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data

Author affiliations: Flatiron Health

This study provides insight into key clinical variables, including histology, biomarker status, and recurrence status of patients with breast cancer in the UK.

Read more

See this research

Date: Wednesday, November 12
Poster Session 5
Poster Code: RWD159

Connect with a flatiron expert

Amit Samani

Amit Samani
Medical Director
Connect on LinkedIn

 

Real-World Study of Breast Cancer Epidemiology and Treatment Patterns: A Pilot Study to Assess EHR-Derived Data in the United Kingdom

Author affiliations: Flatiron Health, Gilead Sciences

This study fills critical gaps in existing data and provides insights into patient demographics, clinical characteristics, and treatment patterns of patients with breast cancer in the UK.

Read more

See this research

Date: Wednesday, November 12
Poster Session 5
Poster Code: RWD163

Connect with a flatiron expert

Blythe-Adamson

Blythe Adamson
Head of Outcomes Research & Evidence Generation, International
Connect on LinkedIn

 

Looking for support in designing and executing HEOR studies with RWE?

Leverage Flatiron’s industry leading multinational oncology data assets and expertise to drive your real-world studies, including:

  • Evaluating comparative- and cost-effectiveness 

  • Modeling long-term survival

  • Examining burden of illness

  • Analyzing treatment patterns

Reach out to learn more about how we partner to accelerate patient access to oncology therapies across the globe.

Request a meeting